On World Sleep Day Idorsia highlights the publication of a global study on the
economic and societal impact of chronic insomnia disorder Chronic insomnia
disorder (CID) is a persistent medical condition that prevents sufferers from
getting restorative sleep 1-3 ; research on wider societal and indirect
economic costs associated with CID have been limited to date 1 New report
indicates annual lost productivity costs of $417 billion in GDP across working
age populations in the countries of focus * and annual “hidden” intangible
wellbeing losses of $239.5 billion 1 Reducing the impact of CID could result in
a boost to the GDP of national economies ranging from 0.64% to 1.31% across the
countries of focus * 1 Idorsia partners with the World Sleep Society on
educational and disease awareness activities focused on the theme: Sleep is
Essential for Health
Allschwil, Switzerland – March 17 , 2023
On World Sleep Day, Idorsia Ltd (SIX: IDIA) highlights the publication of a
first-of-its-kind report by RAND Europe on the economic and societal impact of
chronic insomnia disorder, † “ The Societal and Economic Burden of Insomnia in
Adults: An International Study ”. Idorsia commissioned RAND Europe, an
independent, not-for-profit policy research organization, to help fill some of
the knowledge gaps associated with understanding the financial burden of
chronic insomnia disorder and to deliver new peer-reviewed research into the
impacts of insomnia.
The new report focuses on both the indirect economic costs (i.e.,
non-healthcare related costs) and the “hidden” intangible costs (i.e., costs
that are not directly observed through economic transactions but nonetheless
have impacts on an individual’s health or well-being) associated with chronic
insomnia disorder.
RAND Europe’s findings indicate the indirect economic costs associated with
lost work productivity ranging between $1.8 billion and $207.5 billion (for a
total of $417 billion) in gross domestic product (GDP) across the countries
RAND analyzed. * 1 The intangible annual wellbeing losses range from $1.5
billion and $127.1 billion (for a total of $239.5 billion) in the countries of
focus, which include France, Italy, Germany, Spain, the United Kingdom, the
United States, and Canada. 1,2 The report also provided additional insights on
chronic insomnia disorder.
As part of the company’s ongoing commitment to advance research in insomnia,
Idorsia supports RAND Europe’s recommendation and highlights the importance of:
Incorporating insomnia screening during routine clinical visits Addressing
physician knowledge gaps and improving the identification and management of
insomnia Conducting more research on the prevalence of CID and its societal and
economic impacts
Jean-Paul Clozel, MD and Chief Executive Officer of Idorsia, commented:
“Our scientists have over 20 years of experience in the field of sleep
research, through the orexin system, and continue to work on better
understanding of the science of sleep and chronic insomnia disorder. An example
of our commitment to furthering this understanding is our sponsorship of the
research published by RAND Europe. Their findings are unique by revealing, for
the first time, the indirect economic and ‘hidden’ wellbeing costs of chronic
insomnia disorder. Despite sleep being a biological necessity to ensure optimal
functioning throughout the day, 5 millions of people globally are not getting
restorative sleep due to chronic insomnia disorder. It's important that we
acknowledge chronic insomnia as a legitimate medical condition and recognize
the enormous burden it places on individuals and society as a whole.”
According to the recently published figures, the cost of chronic insomnia
disorder is substantial. In terms of indirect costs, chronic insomnia disorder
was associated with approximately 11 to 18 days of absenteeism, 39 to 45 days
of presenteeism (defined as reduced productivity while at work), and 44 to 54
days of overall productivity loss annually. This equates to an estimated loss
in annual GDP of approximately $170.7 billion for the 12 European countries
analyzed, $19.6 billion for Canada and $207.5 billion for the United States. *
The indirect economic costs reported by RAND are higher than costs reported in
other literature. 1
It was found that people suffering from insomnia, including chronic insomnia
disorder, would be willing to trade, on average, an estimated 14.0% of their
per capita household income in order to recuperate the wellbeing loss
associated with the condition. * From this, population level intangible costs
were estimated to be $92 billion across 12 countries in Europe, $10.7 billion
in Canada and $127.1 billion per year in the United States for those of
working-age range. 1
Marco Hafner, study co-author and RAND Europe research advisor:
“A lack of sufficient, restorative, quality sleep due to chronic insomnia
disorder impacts an individual’s mental and physical health, quality of life,
and productivity, the consequences of which also adversely affect employers,
and global economies. 1 Our research found that eliminating the effects of
chronic insomnia disorder on productivity loss in the workplace would increase
national GDPs in the observed countries by approximately 0.64% to 1.31%,
equating to tens of billions of dollars. These findings underscore the need for
strategies to better mitigate the impact of chronic insomnia disorder through
policy, clinical practice and future research in order to positively impact the
health, well-being and productivity of individuals and society as a whole.”
The report is published on World Sleep Day 202 3 , an annual event organized
by World Sleep Society, an international association whose mission is to
advance sleep health worldwide. Idorsia has partnered with the World Sleep
Society to support with disease awareness education. The importance of sleep to
our overall health has been underlined by the World Sleep Society, which has
chosen to focus World Sleep Day on this central theme for 2023: Sleep is
Essential for Health.
Sleep is one of the three key pillars of health, alongside diet and exercise.
4 A lack of good quality sleep can negatively impact daily life, 5 affecting an
individuals’ ability to make decisions, and limiting their attention span. 6 A
lack of good quality sleep is also associated with physical health issues, such
as an increased risk of hypertension and cardiovascular disease, 5 along with
increased susceptibility to infection. 7 The most important indicator of
getting a good night’s sleep is not just the number of hours spent asleep, but
the quality of that sleep and the impact the sleep (or lack of) has on how you
feel and function the next day. 8
Chronic insomnia disorder, for the approximately 1 in 12 people estimated to
suffer from it, *,1 is a persistent medical that impacts a person’s ability to
fall or stay asleep at least three nights a week for at least three months and
has a negative impact on daytime functioning. 2,3 While direct healthcare costs
related to managing or treating insomnia exists, research on the wider societal
and indirect economic costs associated with chronic insomnia disorder
specifically have been limited to date. 1
* The focus of the RAND research was on general adult populations in 16
high-income, Organization for Economic Co-operation and Development (OECD)
countries: Australia, Austria, Belgium, Canada, Finland, France, Germany,
Greece, Italy, Norway, Portugal, Spain, Sweden, Switzerland, the United
Kingdom, and the United States. Figures for Greece were only included in
prevalence estimates.
† Costs in the RAND Europe report were calculated using modelling methods and
therefore include a number of underlying assumptions which are detailed in the
report itself.
Notes to the editor
About The Societal and Economic Burden of Insomnia in Adults: An International
Study
The objective of this study was to identify and quantify the societal burden
of insomnia and its resultant impacts, both in terms of indirect economic costs
(i.e. non-healthcare related costs) and intangible costs (i.e. costs that are
not directly observed through economic transactions but nonetheless have
impacts on an individual’s health or well-being). Based on these findings, the
report includes independent recommendations for future policy, clinical
practice and research to mitigate the societal and economic impacts of
insomnia.
The focus of this research was on general adult populations in high-income,
Organization for Economic Co-operation and Development (OECD) countries of
Northern, Southern and Western Europe, as well as North America and Australia.
The research methodology included a literature review, secondary database
analysis and the development of a macro-economic model to estimate the indirect
economic costs associated with insomnia. More detailed information on the
methodology can be found here .
The Societal and Economic Burden of Insomnia in Adults: An International Study
was funded by Idorsia Pharmaceuticals Ltd and conducted by RAND Europe under
the advisement of a steering committee whose members were selected for their
subject-matter expertise and objectivity. RAND Europe had full editorial
control and independence of the analyses performed and presented in this
report, which has been peer-reviewed in accordance with RAND Europe’s quality
assurance standards. This work is intended to inform the public good and should
not be taken as a commercial endorsement of any product or service. The views
presented in this report are the authors’ and any remaining errors are their
own.
RAND Europe is a highly regarded, not-for-profit organization whose mission is
to help improve policy and decision making through research and analysis. All
RAND research undergoes rigorous expert review to ensure high standards for
research quality and objectivity.
About World Sleep Society
World Sleep Day is organized by World Sleep Society, an international
association whose mission is to advance sleep health worldwide. World Sleep
Society hosts a biennial scientific congress on sleep medicine aiming to
globally connect sleep professionals and researchers to advance current
knowledge on sleep. A virtual meeting is also underway with details on
worldsleepsociety.org. Follow the excitement on Twitter @_WorldSleep and
facebook.com/WASMF.
About chronic insomnia disorder
Chronic insomnia disorder is defined as difficulty initiating or maintaining
sleep, causing clinically significant distress or impairment in important areas
of daytime functioning. 2,3 This impact on sleep quantity or quality should be
present for at least three nights per week, lasts for at least three months,
and occurs despite an adequate opportunity to sleep. 2, 3
Insomnia is a condition of overactive wake signaling and studies have shown
that areas of the brain associated with wakefulness remain more active during
sleep in patients with insomnia. 9,10 Insomnia as a disorder is quite different
from a brief period of poor sleep, and it can take its toll on both physical
and mental health. 5 It is a persistent condition with a negative impact on
daytime functioning. 3 Idorsia’s research has shown that poor quality sleep can
affect many aspects of daily life, including the ability to concentrate, mood,
and energy levels.
About Marco Hafner
Marco Hafner is an economist and co-author of The Societal and Economic Burden
of Insomnia in Adults: An International Study. He is also lead author of the
2016 report Why Sleep Matters: Quantifying the Economic Costs of Insufficient
Sleep. Hafner was Senior Research Leader at RAND Europe at the time of this
study, where he conducted research at the intersection between health, labor
and international economics.
He has published studies in peer-reviewed academic journals on the
economy-wide effects of ill-health in the population. Hafner holds a Master's
in Economics from the University of Zurich, an MPhil in Economics from UCL, and
conducted doctoral studies at the University of Freiburg. He previously worked
for the Institute for Employment Research in Germany, before joining RAND in
2013.
References Hafner M., Romanelli R.J., Yerushalmi E. & Troxel W.M. The Societal
and Economic Burden of Insomnia in Adults: An International Study. Santa
Monica, CA: RAND Corporation, 2023. The International Classification of Sleep
Disorders, Third edition. (ICSD-3). American Academy of Sleep Medicine, 2014.
The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition
(DSM-5). Washington, DC: American Psychiatric Association; 2013. Castillo, M.
The 3 Pillars of Health. American Journal of Neuroradiology, 2014; 36(1):1–2.
Chattu, V., et al. The Global Problem of Insufficient Sleep and Its Serious
Public Health Implications. Healthcare 2019;7,1. Whitney, P., et al. Feedback
Blunting: Total Sleep Deprivation Impairs Decision Making that Requires
Updating Based on Feedback. Sleep, 2015;38(5):745–754. Ibarra-Coronado E.G., et
al. The Bidirectional Relationship between Sleep and Immunity against
Infections. J Immunol Res 2015; 678164. Kohyama, J., Which Is More Important
for Health: Sleep Quantity or Sleep Quality? Children, 2021; 8(7):542. Buysse,
D.J., et al. Drug Discov Today Dis Models. 2011;8(4):129-137. Levenson, J.C.,
et al. Chest. 2015;147(4):1179-1192.
About Idorsia
Idorsia Ltd is reaching out for more – We have more ideas, we see more
opportunities and we want to help more patients. In order to achieve this, we
will develop Idorsia into a leading biopharmaceutical company, with a strong
scientific core.
Headquartered near Basel, Switzerland – a European biotech-hub – Idorsia is
specialized in the discovery, development and commercialization of small
molecules to transform the horizon of therapeutic options. Idorsia has a
20-year heritage of drug discovery, a broad portfolio of innovative drugs in
the pipeline, an experienced team of professionals covering all disciplines
from bench to bedside, and commercial operations in Europe, Japan, and the US –
the ideal constellation for bringing innovative medicines to patients.
Idorsia was listed on the SIX Swiss Exchange (ticker symbol: IDIA) in June
2017 and has over 1,300 highly qualified specialists dedicated to realizing our
ambitious targets.
For further information, please contact
Andrew C. Weiss
Senior Vice President, Head of Investor Relations & Corporate Communications
Idorsia Pharmaceuticals Ltd, Hegenheimermattweg 91, CH-4123 Allschwil
+41 58 844 10 10
investor.relations@idorsia.com
media.relations@idorsia.com
www.idorsia.com
The above information contains certain 'forward-looking statements', relating
to the company's business, which can be identified by the use of
forward-looking terminology such as 'estimates', 'believes', 'expects', 'may',
'are expected to', 'will', 'will continue', 'should', 'would be', 'seeks',
'pending' or 'anticipates' or similar expressions, or by discussions of
strategy, plans or intentions. Such statements include descriptions of the
company's investment and research and development programs and anticipated
expenditures in connection therewith, descriptions of new products expected to
be introduced by the company and anticipated customer demand for such products
and products in the company's existing portfolio. Such statements reflect the
current views of the company with respect to future events and are subject to
certain risks, uncertainties and assumptions. Many factors could cause the
actual results, performance or achievements of the company to be materially
different from any future results, performances or achievements that may be
expressed or implied by such forward-looking statements. Should one or more of
these risks or uncertainties materialize, or should underlying assumptions
prove incorrect, actual results may vary materially from those described herein
as anticipated, believed, estimated or expected.
Anhang Medienmitteilung PDF
